Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 158

Similar articles for PubMed (Select 23175838)

1.

The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease.

Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, Aguzzi A, Lesné SE.

J Neurosci. 2012 Nov 21;32(47):16857-71a. doi: 10.1523/JNEUROSCI.1858-12.2012.

2.

Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.

Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM.

Nat Neurosci. 2012 Sep;15(9):1227-35. doi: 10.1038/nn.3178. Epub 2012 Jul 22.

3.

Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway.

Chen RJ, Chang WW, Lin YC, Cheng PL, Chen YR.

ACS Chem Neurosci. 2013 Sep 18;4(9):1287-96. doi: 10.1021/cn400085q. Epub 2013 Jul 18.

4.

Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.

Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L.

J Neurosci. 2011 Jan 12;31(2):700-11. doi: 10.1523/JNEUROSCI.4152-10.2011.

5.

Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease.

Um JW, Strittmatter SM.

Prion. 2013 Jan-Feb;7(1):37-41. doi: 10.4161/pri.22212. Epub 2012 Sep 17. Review.

6.

Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein.

Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ, Gunther EC, Nygaard HB, Strittmatter SM.

Neuron. 2013 Sep 4;79(5):887-902. doi: 10.1016/j.neuron.2013.06.036. Erratum in: Neuron. 2013 Oct 16;80(2):531.

7.

Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.

Chung E, Ji Y, Sun Y, Kascsak RJ, Kascsak RB, Mehta PD, Strittmatter SM, Wisniewski T.

BMC Neurosci. 2010 Oct 14;11:130. doi: 10.1186/1471-2202-11-130.

8.

Fyn knock-down increases Aβ, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice.

Minami SS, Clifford TG, Hoe HS, Matsuoka Y, Rebeck GW.

Neurobiol Aging. 2012 Apr;33(4):825.e15-24. doi: 10.1016/j.neurobiolaging.2011.05.014. Epub 2011 Jul 7.

9.

Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β.

Vossel KA, Xu JC, Fomenko V, Miyamoto T, Suberbielle E, Knox JA, Ho K, Kim DH, Yu GQ, Mucke L.

J Cell Biol. 2015 May 11;209(3):419-33. doi: 10.1083/jcb.201407065.

PMID:
25963821
10.

Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models.

Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J.

Cell. 2010 Aug 6;142(3):387-97. doi: 10.1016/j.cell.2010.06.036. Epub 2010 Jul 22.

11.

Cellular prion protein as a therapeutic target in Alzheimer's disease.

Laurén J.

J Alzheimers Dis. 2014;38(2):227-44. doi: 10.3233/JAD-130950. Review.

PMID:
23948943
12.

Tau acts as a mediator for Alzheimer's disease-related synaptic deficits.

Liao D, Miller EC, Teravskis PJ.

Eur J Neurosci. 2014 Apr;39(7):1202-13. doi: 10.1111/ejn.12504. Review.

13.

Hyperphosphorylation of Tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway.

Tokutake T, Kasuga K, Yajima R, Sekine Y, Tezuka T, Nishizawa M, Ikeuchi T.

J Biol Chem. 2012 Oct 12;287(42):35222-33. doi: 10.1074/jbc.M112.348300. Epub 2012 Aug 21.

14.

Memory impairment in transgenic Alzheimer mice requires cellular prion protein.

Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Laurén J, Gimbel ZA, Strittmatter SM.

J Neurosci. 2010 May 5;30(18):6367-74. doi: 10.1523/JNEUROSCI.0395-10.2010.

15.

Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases.

Williamson R, Scales T, Clark BR, Gibb G, Reynolds CH, Kellie S, Bird IN, Varndell IM, Sheppard PW, Everall I, Anderton BH.

J Neurosci. 2002 Jan 1;22(1):10-20.

16.

Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.

Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla FM.

J Neurochem. 2007 Aug;102(4):1053-63. Epub 2007 Apr 30.

PMID:
17472708
17.

Fyn, a potential target for Alzheimer's disease.

Yang K, Belrose J, Trepanier CH, Lei G, Jackson MF, MacDonald JF.

J Alzheimers Dis. 2011;27(2):243-52. doi: 10.3233/JAD-2011-110353. Review.

PMID:
21799250
18.

Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.

Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Rönicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS.

Nature. 2012 May 2;485(7400):651-5. doi: 10.1038/nature11060.

19.

Overcoming barriers and thresholds - signaling of oligomeric Aβ through the prion protein to Fyn.

Wang H, Ren CH, Gunawardana CG, Schmitt-Ulms G.

Mol Neurodegener. 2013 Jul 16;8:24. doi: 10.1186/1750-1326-8-24. Review.

20.

Neuropathogenic role of adenylate kinase-1 in Aβ-mediated tau phosphorylation via AMPK and GSK3β.

Park H, Kam TI, Kim Y, Choi H, Gwon Y, Kim C, Koh JY, Jung YK.

Hum Mol Genet. 2012 Jun 15;21(12):2725-37. doi: 10.1093/hmg/dds100. Epub 2012 Mar 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk